Prelude Therapeutics (Prelude Therapeutics) Earnings Yield (Joel Greenblatt) % : -714.29% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Prelude Therapeutics Earnings Yield (Joel Greenblatt) %?

Prelude Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $18.44 Mil. Prelude Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-132.28 Mil. Prelude Therapeutics's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was -714.29%.

The historical rank and industry rank for Prelude Therapeutics's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

PRLD' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -8905134.9 Med: 0 Max: 5976042.26
Current: 3333.33

During the past 6 years, the highest Earnings Yield (Joel Greenblatt) of Prelude Therapeutics was 5976042.26%. The lowest was -8905134.90%. And the median was 0.00%.

PRLD's Earnings Yield (Joel Greenblatt) % is ranked worse than
99.57% of 1400 companies
in the Biotechnology industry
Industry Median: -14.76 vs PRLD: 3333.33

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Prelude Therapeutics's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

Prelude Therapeutics Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Prelude Therapeutics's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prelude Therapeutics Earnings Yield (Joel Greenblatt) % Chart

Prelude Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Earnings Yield (Joel Greenblatt) %

Get a 7-Day Free Trial

-2.02

-37.45

-138.89

-714.29

Prelude Therapeutics Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Earnings Yield (Joel Greenblatt) %	Get a 7-Day Free Trial															-138.89	-119.05	1,666.67	212.77	-714.29

Competitive Comparison of Prelude Therapeutics's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Prelude Therapeutics's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prelude Therapeutics's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prelude Therapeutics's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Prelude Therapeutics's Earnings Yield (Joel Greenblatt) % falls into.

Prelude Therapeutics Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Prelude Therapeuticss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)	=	EBIT	/	Enterprise Value
	=	-132.277	/	18.436634
	=	-717.47 %

Prelude Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-132.28 Mil.

Prelude Therapeutics (NAS:PRLD) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.

Be Aware

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.

Prelude Therapeutics Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Prelude Therapeutics's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.

Prelude Therapeutics (Prelude Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prelude Therapeutics Inc (NAS:PRLD) » Definitions » Earnings Yield (Joel Greenblatt) %

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Powder Mill Road, Wilmington, DE, USA, 19803

Website

https://www.preludetx.com

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Executives

Krishna Vaddi	director, officer: President, CEO	C/O PRELUDE THERAPEUTICS INCORPORATED, 200 POWDER MILL ROAD, WILMINGTON DE 19803
Bryant David Lim	officer: Chief Legal Counsel, Corp Sec.	C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON PA 19341
Laurent Chardonnet	officer: Chief Financial Officer	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
David P Bonita	director, 10 percent owner	C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Jane Huang	officer: President, CMO	C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
L.p. 667,	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Felix Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Deborah Morosini	officer: EVP, Chief of Clinical Affairs	C/O PRELUDE THERAPEUTICS INCORPORATED, 200 POWDER MILL ROAD, WILMINGTON DE 19803
Andrew Combs	officer: EVP, Head of Chemistry	C/O PRELUDE THERAPEUTICS INCORPORATED, 200 POWDER MILL ROAD, WILMINGTON DE 19803
David J Mauro	officer: Chief Medical Officer	36 TERRELL DRIVE, WASHINGTON CROSS PA 18977